GAITHERSBURG, Md., Jan. 19, 2021 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent, and durable immune response that mimics natural biology, today announced the appointment of Grant Verstandig to its Board of Directors.

NexImmune Appoints Healthcare Innovator Grant Verstandig as New Board Member

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *